2018
Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Olmedo W, Villablanca P, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo C, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez D, Cox-Alomar P, Pyo R, Krishnan P, Wiley J. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis. Vascular 2018, 27: 78-89. PMID: 30501582, DOI: 10.1177/1708538118807522.Peer-Reviewed Original ResearchConceptsPercutaneous peripheral interventionsAccess site complicationsPeripheral interventionsCause mortalitySite complicationsMinor bleedingSystematic reviewEfficacy of bivalirudinProcedural anticoagulant agentLarge randomized trialsSignificant differencesBivalirudin useMajor bleedingIntracranial bleedingBlood transfusionRandomized trialsMyocardial infarctionAnticoagulant agentsClinical studiesBivalirudinBleedingComplicationsPatientsHeparinMortalityCombined Endocardial-Epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease A Systematic Review and Meta-Analysis
Romero J, Cerrud-Rodriguez R, Di Biase L, Diaz J, Alviz I, Grupposo V, Cerna L, Avendano R, Tedrow U, Natale A, Tung R, Kumar S. Combined Endocardial-Epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease A Systematic Review and Meta-Analysis. JACC Clinical Electrophysiology 2018, 5: 13-24. PMID: 30678778, DOI: 10.1016/j.jacep.2018.08.010.Peer-Reviewed Original ResearchConceptsArrhythmogenic right ventricular cardiomyopathyVentricular tachycardiaNonischemic cardiomyopathyIschemic cardiomyopathyProcedural complicationsVT recurrenceEndocardial ablationVT ablationLower riskSystematic reviewLimited single-center studyEndocardial catheter ablationSingle-center studyAcute procedural complicationsA Systematic ReviewRight ventricular cardiomyopathyCause mortalityCatheter ablationEmbase databasesVentricular cardiomyopathyAblation strategyNonsignificant trendSubsequent mortalityPatientsMeta-Analysis
2017
Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials
Romero J, Díaz J, Grushko M, Quispe R, Briceno D, Avendano R, Golive A, Pina I, Natale A, Garcia M, Jorde U, Di Biase L. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. EP Europace 2017, 20: f211-f216. PMID: 29161424, DOI: 10.1093/europace/eux324.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillatorCause mortalityNICM patientsPrimary ProphylacTic Implantable Cardioverter DefibrillatorsRole of ICDUse of ICDsTotal mortalityProphylactic implantable cardioverter defibrillatorProspective randomized clinical trialsCardiac resynchronization therapy pacemakerCause mortality benefitProphylactic ICD placementMedical therapy groupRandomized clinical trialsRandom-effects modelSignificant reductionFixed-effects modelMean followMortality benefitICD groupIschemic cardiomyopathyMedical therapyICD placementTreatment arms